Ефективність та прогностичне значення основних класів препаратів для лікування ішемічної хвороби серця в осіб віком понад 60 років

Abstract

The objective: of the work is to determine the frequency of use and association with the life expectancy of individual classes and combinations of drugs for the treatment of ischemic heart disease (IHD) in patients over 60 years of age. Materials and methods. 454 case histories of patients aged 60–90 years were analyzed. All the examined were first hospitalized in the hospital and were later observed with the main diagnosis of coronary artery disease: stable exertional angina I–IIIFC. The end points of observation were considered the last hospitalization at the time of 2017 or the onset of the end point. The patient’s death, based on which the life expectancy indicator was studied (determined by the year / age of death), was identified as the end point. Results. It was shown that in 1997–2003, the most commonly prescribed drug classes were: β -blockers (64.8%), ACE inhibitors (іngіbіtori angіotenzinperetvoryuyuyu enzyme) 70.2%, ASA (acetylsalicylic acid) 66,2% and nitroglycerin preparations (36.4%). Statins were rarely prescribed 18.9%. In 2015–2017, drugs from the group of HMG-CoA reductase inhibitors, according to the analysis, began to be administered in 91.0% of cases. Almost not used nitroglycerin series drugs – 9.24%. Conclusion. The results indicate that patients receiving ASA, statins and beta blockers – 81.4±3.16 years; ASA, statini and ACE inhibitors – 80.1±1.71 years; ASC, statins and blockers of Ca-channels 78.7±4.24 years. As a result of the use of logistic regression, we constructed an equation according to which the individual life expectancy of patients can be predicted depending on which drugs they treat the patient. Key words: ischemic heart disease, patients of the elderly, features of treatment.